DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Candidiasis - Pipeline Review, H2 2016" report to their offering.
The report provides comprehensive information on the therapeutics under development for Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects.
The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Scope:
- The report provides a snapshot of the global therapeutic landscape of Candidiasis
- The report reviews pipeline therapeutics for Candidiasis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Candidiasis therapeutics and enlists all their major and minor projects
- The report assesses Candidiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
Companies Mentioned:
- Amplyx Pharmaceuticals, Inc.
- Bakker Medical Srl
- Biomar Microbial Technologies
- Biosergen AS
- Cellceutix Corporation
- Cidara Therapeutics, Inc.
- Daewoong Pharmaceutical Co., Ltd.
- Dermala Inc
- General Biologicals Corporation
- Grupo Ferrer Internacional, S.A.
- Hsiri Therapeutics, LLC
- iCo Therapeutics Inc.
- Matinas BioPharma Holdings, Inc.
- Nanomerics Ltd
- Novabiotics Limited
- NovaDigm Therapeutics, Inc.
- Onxeo SA
- Scynexis, Inc.
- Sealife PHARMA GMBH
- TGV-Laboratories
- Viamet Pharmaceuticals, Inc.
- Wellstat Vaccines, LLC
For more information about this report visit http://www.researchandmarkets.com/research/pqqgf4/candidiasis
Related Reports:
